Velocity Clinical Research

1. AstraZeneca Pharmaceuticals LP $29,306,097 500 payments
2. Moderna TX, Inc. $8,360,655 466 payments
3. Pfizer Inc. $7,874,262 508 payments
4. Sanofi Pasteur Inc. $5,620,320 200 payments
5. Bavarian Nordic A/S $4,054,384 773 payments
6. AstraZeneca UK Limited $2,246,503 42 payments
7. Novo Nordisk AS $1,980,429 4,538 payments
8. Merck Sharp & Dohme Corporation $796,286 9 payments
9. Novartis Pharmaceuticals Corporation $572,957 22 payments
10. GlaxoSmithKline, LLC. $546,692 107 payments

1. A Phase III Randomized Double-blind Placebo-controlled Multicenter Study in Adults to Determine the Safety Efficacy and Immunogenicity of AZD1222 a Non-replicating ChAdOx1 Vector Vaccine for the Prevention of COVID-19 $12,666,787 22 payments
2. A Phase 3 Multicenter Placebocontrolled Randomized Observerblinded Trial to Evaluate the Efficacy Safety Tolerability Immunogenicity and Lot Consistency of A 6Valent Ospabased Lyme Disease Vaccine in Healthy Participants 5 Years of Age $4,346,009 66 payments
3. A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older $3,394,026 245 payments
4. Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older $2,928,334 107 payments
5. A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health $2,473,925 67 payments
6. A Phase IIb Randomized Double blind Placebo controlled and Open label Active Comparator Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus $2,077,162 37 payments
7. A Phase 3 Study to Evaluate the Efficacy Immunogenicity and Safety of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults $2,029,126 188 payments
8. A Phase 1/2, Parallel-group, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Ranging Study to Evaluate the Safety and Immunogenicity of a Second Generation Structurally Designed Pandemic Influenza H5 HA mRNA Vaccine in Healthy Adults Aged 18 Years and Older $1,962,887 19 payments
9. A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Participants living with Obesity or Overweight with Comorbidity $1,932,128 21 payments
10. A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS $1,802,552 60 payments

1. Patient care $32,893 4 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.